We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Regenxbio is challenging in federal court the FDA’s recent decision to place holds on the company’s two trials for retinal disease therapies, saying the agency did not follow its own regulations in handling the matter.